Cerliponase alfa

(Brineura)

Cerliponase alfa

Drug updated on 11/13/2023

Dosage FormInjection (intraventricular: 150 mg/5 mL (30 mg/mL))
Drug ClassHydrolytic lysosomal N-terminal tripeptidyl peptidases
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.

Product Monograph / Prescribing Information

Document TitleYearSource
Brineura (cerliponase alfa) Prescribing Information.2020BioMarin Pharmaceutical Inc., Novato, CA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines